Jones Trading Reiterates Buy Rating on Rezolute (RZLT) following FDA lift of clinical hold on RZ358

Jones Trading analyst Catherine Novack reiterated a Buy rating and $12.00 price target on Rezolute (NASDAQ: RZLT).

The analyst commented: "RZLT announced FDA lifted the partial clinical hold for ersodetug (RZ358) in congenital hyperinsulinism (CHI). The ongoing pivotal study will now include US patients, with topline data in 2H25 (previously mid-2025). Our forecasts already include a US commercial launch, so the announcement has a modest impact to our estimates, but it's encouraging to have this regulatory overhang resolved ahead of next year's pivotal readout."

For an analyst ratings summary and ratings history on Rezolute click here. For more ratings news on Rezolute click here.

Shares of Rezolute closed at $4.35 yesterday.

You May Also Be Interested In

• Evercore ISI Starts Alvotech SA (ALVO) at Outperform
• BitGo Holdings (BTGO) PT Lowered to $11 at Mizuho
• StubHub Holdings (STUB) PT Lowered to $11 at Mizuho